News Summary

EUCROF at the 2nd Kiev Clinical Research Forum The 2nd Kiev Clinical Research Forum took place on 16 – 17 May, 2019. The Conference, organized by PHARMASICH (a EUCROF member) with EUCROF’s patronage, was a great success. Over 330 attendees...

In the framework of the third EPTRI (European Paediatric Translational Research Infrastructure) General Assembly Meeting, held in Madrid on March 27-28th, an Open Day Meeting was organised on March 27th at the Ministry of Health. The meeting has foreseen a...

Our last meeting at the EMA in London! After many years of visiting London to meet with the EMA, representatives of EUCROF (Dr Martine Dehlinger-Kremer, Dr Dagmar Chase and Simon Lee photographed in the lobby area) attended the very last...

Further to the elections at the General Assembly on 7th December 2018 in London, EUCROF is very pleased to announce the Executive Board members for the next mandate (a mandate is over 2 years). Following the progress made in the...

The stakeholder Meeting “Shaping regulatory science to 2025” took place at the EMA in London on Wednesday, 24 October 2018. EUCROF attended, represented by Dr Martine Dehlinger-Kremer. The aim of the meeting was to gather insight from stakeholders on the...

On Thursday and Friday next week, the “Better Medicines for Children” Meeting (DIA/EFGCP) will take place in Brussels. EUCROF will be represented by its President, Martine Dehlinger-Kremer, its Vice-President, Dr Stefano Marini, together with Dr Dagmar Chase. Martine Dehlinger-Kremer will...

The Clinical Trial Facilitation Group (CTFG) Stakeholder Meeting will take place in Bonn on Wednesday, 24 October 2018. The meeting will develop the following topics: EUCROF will be attending, represented by Dr Stefano Marini and Dr Dagmar Chase. Kindly click...

Applied Clinical Trials published in its Volume 26, Issue 10, a paper called “The Shifting Perspectives on Pharmacovigilance in Europe” including some highlights and a link to the paper prepared by the EUCROF PharmacoVigilance Working Group on the EUCROF website....

According to recent GVP module VI Revision 2, from 22 NOV 2017 non-serious ADRs from the market in Europe should be submitted to EMA/Eudravigilance within 90 days. This new updated GVP module also applies to non-interventional studies. This may have...